AUS
NZ
UK
CA
USA
IND
The Environmental Group Limited (ASX:EGL) turned out to be a leading gainer at the close of the trading session today, soaring massively by 62.857 %. The shares closed at AUD 0.057 as compared to the previous close of AUD 0.035. The session represented Daily Volume of 431,056 shares today. However, the upside contrasts with the stockâs recent downward trend. The shares have offered a negative return of 36.36% over the last three months.
The Environmental Group Limited is involved in delivering environmental solutions to its clients. Through its subsidiary Baltec, EGL provides heating and cooling systems, silencers, fogging systems, guillotine dampers, bypass and HRSG exhaust stacks, and diverter dampers. Through its subsidiary Total Air Pollution Control Pty Ltd, the company is involved in designing and delivery of electrostatic precipitators, fabric filters and gas cleaning systems.
On 7 January 2019, the company announced the acquisition of RCR Energy Service Assets aimed at business strategy of building Bio/Waste to Energy capability. RCR Tomlinson Energy Service business is a leader in offering Bosch steam and hot water boilers, Tomlinson vertical steam boilers, packaged water tube boilers and Intec thermal fluid heaters.
Imagion Biosystems Limited (ASX:IBX): The Healthcare stock demonstrated an impressive 29.63% jump in todayâs trading session, closing at AUD 0.035 with a market capitalization of AUD 8.71 million. However, the price of the scrip is trending downward at 46% from the past three months.
 Imagion Biosystems is involved in early detection and localization of cancer and other human diseases based on nanobiotechnology (magnetic nanoparticles). The company utilizes PrecisionMRX Nanoparticles and Superparamagnetic Relaxometry technology. In September 2018, Imagion Biosystems achieved a key milestone in its first-in-human testing, for its first intended clinical product. The company will now move its product toward testing for the detection of HER2 breast cancer cells in the lymph nodes. The companyâs manufacturing partner will produce the first batch of the HER2 nanoparticle test component anticipating the first-in-human study this year.
As per half-yearly financial results, Imagion Biosystems recorded 4.42% increase to AUD 251,615 in Revenue from Ordinary Activities. The Loss for the half year increased by 1.6% to AUD4,218,881 as on 30 June 2018. The company reported Total Expenses of $4.4 million, slightly less than the projections.
IPB Petroleum Limited (ASX:IPB): The shares of the Energy player zoomed by 15.385% today, settling at AUD 0.030 as compared to the previous close of AUD 0.026. IPB stock has witnessed a strong performance growth of 23.81% this year. The Earnings Per Share of the company stands at AUD - 0.003.
The oil & gas explorer has strategic ownership in the highly resourceful southern margin of the Browse Basin Offshore North Western Australia. The companyâs oil & gas assets include full ownership of WA-424-P, WA-471-P and WA-485-P. During 2018, the company has successfully renewed WA-424-P permit for further five years. Various exploration program commitments on WA-471-P and WA-485-P have been approved by the regulatory authority. The company successfully completed an oversubscribed capital raising of $800k in July placing the company at a strategic financial advantage.
IPB recorded Net Loss After Tax (excluding impairment loss) of $0.470 million for the year ending 30 June 2018 as compared to $0.477 million in the previous year. Recurring expenses related to depreciation, administration and other related costs decreased from $0.480 million in 2017 to $0.434 million. The company reported a decrease in Net Assets from $3.095 million in FY 2017 to $2.890 in FY 2018.
Disclaimer
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.
